StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Saphnelo (anifrolumab) — Worldwide product sales by Quarter

Saphnelo (anifrolumab) — Worldwide product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Saphnelo (anifrolumab) — Worldwide product sales: $209M in Q2 2026, up 25.1% from a year earlier. That is the highest of the 20 quarters on record here.

Latest, Q2 2026
209
Period ended Jun 30, 2026
Change on a year earlier
+25.1%
167 in Q2 2025
History
20 quarters
Since Q3 2021
Sources
20
Documents cited below

Where the Q2 2026 figure comes from

“|| Saphnelo | | 209 | | 25 | | 24 | | 175 | | 21 | | 7 | | 68 | | 64 | | 19 | | 58 | | 51 | | 8 | | 31 | | 38”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSaphnelo (anifrolumab) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026209+25.1%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026171+25.7%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025203+38.1%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025180+45.2%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025167+49.1%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025136+49.5%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024147+65.2%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024124+63.2%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024112+64.7%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202491+93.6%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202389+85.4%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 202376+130.3%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 202368+183.3%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202347+327.3%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 202248+585.7%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 202233+3,200.0%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up saphnelo (anifrolumab) — Worldwide product sales

Cite this data

StockData. (2026). AstraZeneca Saphnelo (anifrolumab) — Worldwide product sales ($M), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-saphnelo-world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.